Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RORB | Q92753 | 5/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185793 | 0.92 | DRD4 (0.47) | CCNA2CDK2MYCWDR5MAPT | |
| SCHEMBL257438 | 0.85 | ADORA3 (0.54) | MYCWDR5MAPTKMT2AMEN1 | |
| SCHEMBL11285727 | 0.84 | ALDH1A1 (0.49) | MYCWDR5MAPTFBP1ALDH1A1 | |
| SCHEMBL257436 | 0.83 | RORB (0.66) | MAPTKMT2AMEN1RORBRORC | |
| SCHEMBL165773 | 0.81 | ADORA3 (0.61) | MAPTALDH1A1HSD17B10RORBKDM4E | |
| SCHEMBL14264449 | 0.80 | FBP1 (0.47) | CCNA2CDK2MAPTCDK5CDK5R1 | |
| SCHEMBL13536655 | 0.79 | HPGD (0.49) | CCNA2CDK2MAPTCDK5CDK5R1 | |
| SCHEMBL178218 | 0.78 | ADORA3 (0.60) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL257616 | 0.78 | ADORA3 (0.64) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL178204 | 0.78 | CDK5 (0.58) | CCNA2CDK2CDK5CDK5R1RORB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| EP-2380631-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2349484-A2 | HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS | Novartis AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| CN-102119047-A | Heteroaryl derivatives as DGAT1 inhibitors | NOVARTIS AG | 2011-07-06 | — | — | CN | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| WO-2010007046-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007046-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022513-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | CCNA2 2404/4885CDK2 2340/4885MYC 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.